Objective: Although some new drugs for castration-resistant prostate cancer are available, docetaxel still plays an important role in castration-resistant prostate cancer treatment. In this study, we evaluated the efficacy and safety of docetaxel and prednisolone in patients with castration-resistant prostate cancer. Methods: We conducted a retrospective chart review of castration-resistant prostate cancer patients who received docetaxel and prednisolone at 14 hospitals in the Sapporo Medical University Urologic Oncology Consortium from August 2004 to December 2011. Results: A total of 140 patients with castration-resistant prostate cancer received docetaxel and prednisolone (median age, 73.8 years; median prostate specific antigen, 54.7 ng/ml). A median of six cycles (range: 1-43) of docetaxel and prednisolone was administered per patient. Median follow-up was 13.7 months. Median overall survival was 22.0 months. The log-rank test revealed that prostate specific antigen before docetaxel and prednisolone (<50 ng/ml) and the prostate specific antigen reduction rate (≥30%) were associated with overall survival (P < 0.001 and P < 0.001, respectively). Eighty patients (57.1%) achieved a prostate specific antigen reduction rate of over 30%. All except two (97.5%) reached 30% prostate specific antigen reduction within five cycles of docetaxel and prednisolone. There were two (1.4%) treatment-related deaths due to adverse events, which were interstitial lung disease, and febrile neutropenia and bacterial pneumonia. Interstitial lung disease occurred in 14 (10.0%) patients within a median of 2.5 cycles of docetaxel and prednisolone. Grade 5 interstitial lung disease was seen after three cycles of docetaxel and prednisolone. Conclusions: If a prostate specific antigen reduction rate of over 30% is not obtained within five cycles of docetaxel and prednisolone, other treatment options should be considered. Although most patients safely received docetaxel and prednisolone, we must always keep interstitial lung disease in mind as a possible lethal adverse event.
Introduction
Docetaxel and prednisone ( prednisolone in Japan) (DP) is valid for castration-resistant prostate cancer (CRPC), as verified by Tannock et al. (1) who conducted the TAX-327 trial and reported the results in 2004. We have used it for CRPC for a relatively long time because DP was the only treatment option that was approved in Japan before 2014. Although the efficacy of DP for CRPC was shown up to 10 cycles in the TAX-327 trial (1), patients often continued docetaxel chemotherapy >10 cycles as long as it was effective because there was no alternative other than best supportive care in the docetaxel era.
Recently, several drugs for CRPC have become available or are being prepared for launching (2) (3) (4) (5) (6) (7) . Two large randomized control trials demonstrated that the inhibition of androgen biosynthesis by abiraterone acetate and multiple-step inhibition of androgen-receptor signaling by enzalutamide prolonged overall survival among patients with metastatic CRPC (mCRPC) who previously received chemotherapy. Furthermore, both randomized trials of abiraterone and enzalutamide in the pre-docetaxel setting showed that these drugs significantly decreased the risk of radiographic progression and death and delayed the initiation of chemotherapy in mCRPC patients. However, there is no evidence on the sequencing of abiraterone, enzalutamide and docetaxel. To select a treatment among these drugs at the diagnosis of CRPC, predictive factors for the survival benefit of DP and for the timing to switch to another treatment should be determined. To assess these factors, we conducted a multi-institutional study and analyzed the efficacy and safety of real-world DP treatment for patients with CRPC.
Patients and methods
We retrospectively investigated the medical charts of CRPC patients who received DP in 14 institutes of the Sapporo Medical University Urologic Oncology Consortium (SUOC) from August 2004 to December 2011. This study was approved by the Institutional Review Board for Clinical Research at Sapporo Medical University in July 2012 (#24-62).
Eligible patients in this study were as follows: patients whose prostate specific antigen (PSA) increased consistently 3 points or more who complained of symptom worsening or had imaging findings of progression in spite of surgical or medical castration with at least one antiandrogen therapy. In this study, the dose of docetaxel used ranged from 50 to 75 mg/m 2 depending on the individual clinician and oral 5 mg prednisolone was generally administered twice daily. The efficacy of chemotherapy was determined by overall survival (OS) from the date of DP administration. We evaluated adverse events according to the National Cancer Institute Common Terminology Criteria for adverse events, version 4.0. The Kruskal-Wallis test and Wilcoxon signed-rank test with Bonferroni correction were used to compare PSA values among groups. We demonstrated OS after DP with the Kaplan-Meier curve. The difference in OS between two groups was analyzed using the log-rank test. We assessed the prognostic factors for predicting OS after DP using the Cox proportional hazards model. In all analyses in this study, P < 0.05 was regarded as statistically significant. Statistical analyses were performed using SPSS 15.0 (SPSS Inc., Chicago, IL, USA).
Results

Dose and duration of DP
The patients' backgrounds at the time of prostate cancer diagnosis and at the beginning of DP are shown in Tables 1 and 2 , respectively. One hundred forty patients received a total of 1042 cycles of DP in the 14 institutes. The median number of cycles of DP was 6 (range: 
PSA according to metastatic site
Of the 140 patients, 25 (17.9%) did not have metastatic disease but PSA elevation alone, 95 (67.9%) had lymph node and/or bone metastasis without other visceral metastasis, and the remaining 20 (14.3%) had lung and/or liver metastasis. The median PSA levels at initial DP in the groups with PSA elevation alone, lymph node and/or bone metastasis and lung and/or liver metastasis were 33.6 ng/ml (range: 4.1-899), 54.2 ng/ml (range: 0.2-11204.8) and 113.0 ng/ml (range: 10.4-4900), respectively. There was a statistically significant difference in PSA between the group with PSA elevation alone and that with lung and/or liver metastasis (P = 0.001)
Treatment efficacy
A decrease in PSA was observed in 93 (66.4%) patients and the nadir was fixed in 64 (45.7%). A median of five cycles (range: 2-20) of DP was needed to reach the PSA nadir. There were 68 (48.6%) and 80 (57.1%) patients who achieved 50 and 30% reductions in PSA after DP, respectively. A rise in PSA was observed in 30 (21.4%) patients after starting DP. Of these 30 patients, 22 had a PSA decrease after the PSA rise but the PSA continued to increase in the remaining 8. Finally, the PSA values declined to less than baseline after additional DP in 14 (46.7%) of the 30 patients. Of these 14 patients, 8, 3, 1 and 2 achieved PSA declines to less than baseline after 2, 3, 4 and 8 or more cycles of DP, respectively. At the time of investigation, 69 patients survived, 61 had died of prostate cancer and 10 had died of other causes. The median OS after initial DP was 22.0 months (Fig. 1) . The median OSs after initial DP in the groups with PSA elevation alone, lymph node and/or bone metastasis and lung and/or liver metastasis were 25.3 months, 13.7 months and 4.4 months, respectively.
Prognostic factors
We investigated prognostic factors for OS and the hazard ratios in patients who received DP (Table 3) . Among the baseline variables, PSA and the metastatic site were statistically significant prognostic factors in univariate analysis. However, only a PSA value of <50 ng/ml was an independent factor in multivariate analysis in this study. The median OS times after DP were 33.2 and 13.7 months in groups with PSA levels of <50 ng/ml, and 50 or more, respectively (P < 0.001) ( Fig. 2A) .
In addition, patients who achieved a decline of PSA of over 30% after DP at least one time survived significantly longer than those who did not. The median OS times after DP were 27.2 months in former group and 13.7 in the latter one (P < 0.001) (Fig. 2B) . Although the median OS in patients who achieved 50% reduction in PSA was similarly good (27.5 months vs. 14.4 months, P = 0.001), a 30% reduction in PSA as a cutoff was superior to 50% because of the lower P value in the case of 30% reduction.
Eighty patients (57.1%) achieved a PSA decline of over 30%, and 78 (97.5%) of them did so within five cycles (median: two cycles).
Adverse events
Adverse events in this study are summarized in Table 4 . White blood cell and neutrophil count decreases were seen in ∼90% of the patients. Grade 3 or more adverse events such as anemia and platelet count decreases were rare. Grade 3 or more white blood cell decreases and neutrophil count decreases were observed within a median of 7 days (range: 4-14) and 8 days (range: 4-16), respectively.
There were two treatment-related deaths due to severe adverse events: interstitial lung disease (ILD), febrile neutropenia and bacterial pneumonia. ILD occurred in 14 (10.0%) patients after one cycle (four patients), two cycles (3 patients), three cycles (2 patients), four cycles (2 patients), five cycles (1 patient) and seven cycles (2 patients) of DP. Grade 5 ILD was seen after three cycles of DP. Grade 3 or more nonhematological adverse events were rare, though Grade 4 anorexia and hypotension were seen in one patient each.
Discussion
The median OS times of patients who received DP every 3 weeks in the TAX 327 study were 18.9 months in the initial report (1) and 19.2 months in the updated one (8) . Although our study demonstrated better median OS than the TAX 327 study (1), the reason for this result seemed to be the difference in PSA values between the two studies. The median PSA values in the TAX 327 study and our study were >100 ng/ml and ∼50 ng/ml, respectively. Similarly, patients who started DP with a lower PSA value had longer OS than those with a higher one in this study. Thus, DP should be considered for CRPC patients with lower PSA, although lead time bias may exist in this comparison.
Pond et al. (9) reported TAX 327 trial subgroup analysis of the association between the metastatic site and prognosis. The median OS times were worsened in the order of the metastatic site: lymph node only, bone only, bone and lymph node, lung and liver in their report. They revealed that the site of the metastasis was an independent prognostic factor and visceral metastasis was unfavorable. Although our study showed similar results for OS, the metastatic site was not a significant prognostic factor. This result seemed to be associated with the small number of patients with visceral metastasis and their significantly higher PSA values. Previous studies on PSA surge/flare-up reported that the rate of this phenomenon was from 7.6 to 20.0% (10) (11) (12) (13) (14) (15) . It was 19.0% in postmarketing surveillance in Japan (16). Berthold et al. (17) suggested that early increases in PSA should be ignored. Of 335 patients who received DP every 3 weeks, 22 (6.6%) had increased PSA and 10 (45.5%) finally achieved a 50% PSA reduction. At least four cycles (12 weeks) of DP are recommended even if PSA surge/flare-up occurs. Ide et al. (14) reported a transient PSA rise in 3 of 20 (15.0%) CRPC patients treated with DP and concluded that at least three cycles of DP should be performed. In our study, 14 (10.0%) patients experienced PSA surge/flare-up and a PSA decline to less than baseline PSA in a median of three cycles. Our results were similar to those in previous studies and supported their conclusions.
Armstrong et al. (18) reported that a 30% or more PSA decrease within 3 months was one of the prognostic factors that correlated with OS. Similarly, our study showed a significant difference in the median OS between patients who achieved a 30% or more PSA reduction of at least at one point and those who did not. Of the patients who achieved a 30% PSA reduction, 97.5% reached this rate within five cycles of DP. Therefore, it is likely that additional DP may be useless for patients who do not achieve a 30% PSA reduction within five cycles. If there is any other option for CRPC, these patients should switch from DP to the other option.
As hematological adverse events, white blood cell decreases and neutrophil count decreases frequently occurred. About half of the patients experienced a Grade 4 neutrophil count decrease. However, we can roughly predict the timing of white blood cell decreases and neutrophil count decreases. On the other hand, we cannot predict when ILD will occur despite its lethal potential. Although ILD was common within three cycles or fewer of DP (median: 2.5 cycles) in this study, two patients had ILD at seven cycles. Previously, the incidences of ILD were 2 of 43 (2.3%) patients and 2 of 149 (1.3%) in a Phase II trial (19) and post-marketing surveillance (16) in Japan, respectively. In the present study, the incidence of ILD was 10.0%, which was relatively higher than that in previous ones. Furthermore, of the 14 patients with ILD, 1 (7.1%) died of severe ILD during DP and we previously published a case report about this in another journal (20) . Miura et al. (21) reported three deaths (5.5%) due to acute respiratory distress syndrome (ARDS) associated with DP treatment. Thus we must always keep in mind the possibilities of ILD and ARDS during DP.
Limitations
First, this study was a retrospective study. Therefore, the subjects were heterogeneous and the criteria about discontinuation or dose reduction were different in individual institutes. Second, imaging examinations after DP were not always conducted. Progression was determined by PSA in most of the patients.
Conclusions
This study showed longer OS in CRPC patients who started DP with lower PSA values, the cutoff for which was 50 ng/ml, than in previous reports. There is a possibility that the response to DP within five cycles can predict the survival benefit of following DP. If a reduction of PSA of over 30% from baseline is not observed within five cycles of DP, we should switch the treatment to another one. Although most of the patients safely received DP, we must always be aware of the possibility of ILD as a lethal adverse event. 
